Amicus Therapeutics, Inc.

Amicus Therapeutics Misses on EPS, Stock Down 3.69%

The earnings report indicates that Amicus Therapeutics reported a loss per share of $0.25, which was slightly worse than expected. The stock reacted negatively, dropping 3.69%, likely reflecting investor disappointment over the EPS miss and the lack of revenue information. Without further commentary from management, the outlook remains unclear.